期刊文献+

非小细胞肺癌少见驱动基因及相应靶向药物的研究进展 被引量:5

下载PDF
导出
摘要 近几年,随着肿瘤精准医学研究的持续进展,一系列肺癌相关致癌驱动基因相继被明确,全球多项临床研究证实通过靶向药物治疗能有效改善携带相应驱动基因NSCLC患者的预后、延长生存期,因此肺癌的分型由简单的组织病理学分类,细化为以相关致病基因为主的分子分型,治疗也从传统的细胞毒性治疗渐渐转化为以分子分型为主的个性化精准靶向治疗,避免了对机体正常组织细胞产生损伤。现对NSCLC中少见的六类驱动基因及其靶向药物的研究进展进行综述。
机构地区 云南省肿瘤医院
出处 《临床肺科杂志》 2024年第3期453-456,共4页 Journal of Clinical Pulmonary Medicine
基金 云南省科技厅-昆医联合专项研究项目(No.202101AY070001-182)。
  • 相关文献

参考文献6

二级参考文献24

  • 1朱晓莉,林勇,唐剑英,张祖贻.C-erb B-2基因在肺癌中表达意义的临床研究[J].东南大学学报(医学版),2006,25(1):41-43. 被引量:6
  • 2Tiseo M,Loprevite M,Ardizzoni A.Epidermalgrowth factor receptor inhibitors:a new prospective in the treatment of lung cancer[J].Curr Med Chem Anticancer Agents,2004,4(2):139-148.
  • 3Wang S E,Narasanna A,Perez-Torres M.HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors[J].Cancer Cell,2006,10(1):25-38.
  • 4Buttitta F,Barassi F,Fresu G,et al.Mutational analysis of the HER2 gene in lung tumors from Caucasian patients:mutations are mainly present in adenocarcinomas with bronchioloalveolar features[J].Int J Cancer,2006,119(11):2586-2591.
  • 5Ugocsai K,Mándoky L,Tiszlavicz L,et al.Investigation of HER2 overexpression in non-small cell lung cancer[J].Anticancer Res,2005,25(4):3061-3066.
  • 6Cappuzzo F,Varella-Garcia M,Shigematsu H,et al.Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients[J].Clin Oncol,2005,23(22):5007-5018.
  • 7Petit A M,Rak J,Hung M C,et al.Neutraizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinase down-regulate vagcular endothelial growth factor production by tumor cells in vitro and invivo:angiogenic implication for signal transduction therapy of solid tumors[J].Am J Pathol,1997,151(6):1523-1530.
  • 8Bunn P A,Helfrich B,Sariano A F,et al.Expression of Her-2/neu in human lung cancer cell lines immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents[J].Clin Cancer Res,2001,7(10):3239-3250.
  • 9Langer C J,Stephenson P,Thor A,et al.Trastuzumab in the treatment of advanced non-small cell lung cancer:is there a role?Focus on Eastern Cooperative Oncology Group Study 2598[J].J Clin Oncol,2004,22(7):1180-1187.
  • 10Scheuer W,Friess T,Burtscher H,et al.Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models[J].Cancer Res,2009,69(24):9330-9336.

共引文献28

同被引文献97

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部